Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Vindesine API Manufacturers & Suppliers
1 verified results
Commercial-scale Suppliers
Employees: 550+
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Vindesine | CAS No: 53643-48-4 | GMP-certified suppliers
A medication that treats hematologic malignancies including acute leukemia and lymphomas by inhibiting cancer cell division, used especially for resistant or relapsed cases in combination therapy.
Therapeutic categories
Primary indications
- For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Product Snapshot
- Vindesine is available as an injectable small molecule formulated as a powder for solution for intravenous and parenteral use
- It is primarily indicated for hematologic malignancies including acute leukemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis
- Vindesine is approved and marketed in Canada, with investigational status in other regions
Clinical Overview
Pharmacodynamically, vindesine exerts its antitumor effects by disrupting mitotic spindle formation, thereby arresting cells in metaphase during mitosis. It is a potent inhibitor of tubulin polymerization, which impedes the normal dynamics of microtubules required for chromosome segregation. Vindesine’s mitotic arrest potency exceeds that of vincristine by approximately threefold and vinblastine by nearly tenfold at moderate levels of cell cycle arrest. The agent demonstrates cell-cycle specificity, primarily affecting cells in the S phase, and has shown efficacy in patients who have relapsed despite prior vincristine-containing treatments.
Key pharmacokinetic properties include metabolism primarily through cytochrome P450 3A4 isoenzymes, leading to considerations regarding drug-drug interactions and clearance variability. Vindesine has a narrow therapeutic index, necessitating careful dosing and monitoring. Major safety concerns include myelosuppression and neurotoxicity, which are dose-limiting toxicities commonly observed during therapy. Cardiovascular effects are also noted, consistent with its classification as a cardiotoxic agent. Monitoring hematologic parameters and neurological status is critical during treatment.
Vindesine is categorized as an antimitotic, antineoplastic, and immunosuppressive phytogenic agent, classified under the broader vinca alkaloid family. It is approved for clinical use in several countries but remains investigational or restricted in others, reflecting its specialized application.
When sourcing vindesine API, quality considerations should emphasize stringent control of impurities, consistent potency, and compliance with relevant pharmacopeial standards. Due to its cytotoxic nature and narrow therapeutic window, manufacturers must ensure robust manufacturing controls and validated analytical methodologies to confirm identity, purity, and stability. The API should be handled under appropriate containment to protect personnel and maintain material integrity.
Identification & chemistry
| Generic name | Vindesine |
|---|---|
| Molecule type | Small molecule |
| CAS | 53643-48-4 |
| UNII | RSA8KO39WH |
| DrugBank ID | DB00309 |
Pharmacology
| Summary | Vindesine is a tubulin-binding agent that inhibits microtubule formation, leading to cell cycle arrest during metaphase of mitosis. It exhibits specificity for the S phase and demonstrates increased potency compared to vincristine and vinblastine in inducing mitotic arrest. Vindesine is utilized for treating various hematologic malignancies, including acute leukemia and malignant lymphoma, by disrupting tubulin beta-1 chain function to inhibit cancer cell proliferation. |
|---|---|
| Mechanism of action | Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase. |
| Pharmacodynamics | Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer. Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in <i>in vitro</i> studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Tubulin beta-1 chain | Humans | inhibitor |
ADME / PK
| Half-life | 24 hours. |
|---|---|
| Protein binding | 65-75% |
| Metabolism | Hepatic |
Formulation & handling
- Vindesine is administered parenterally, primarily as a powder for intravenous injection.
- As a small molecule with moderate lipophilicity (LogP 2.79), vindesine requires careful dissolution and handling for injection formulations.
- CYP3A4-mediated metabolism necessitates caution with concomitant use of CYP3A4 inhibitors or inducers such as grapefruit products and St. John's Wort.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient is marketed in Canada with patent protection expiring in 2026, after which generic competition is expected to increase. The product is currently in the mature phase of its lifecycle with established market presence. |
|---|
| Markets | Canada |
|---|
Supply Chain
| Supply chain summary | Vindesine is available in the Canadian market with branded products such as Eldisine Inj 5mg/2ml. The presence of branded formulations indicates originator companies maintain production and supply in this region. Patent expiry status is not provided, so the potential for generic competition cannot be assessed from the current data. |
|---|
Vindesine is a type of Antimicrobial agents
Antimicrobial agents are a vital subcategory within the pharmaceutical industry, specifically developed to combat microbial infections. These agents, also known as antibiotics, play a crucial role in treating various types of bacterial, fungal, viral, and protozoal infections.
Antimicrobial agents act by inhibiting the growth or killing the microorganisms responsible for infections. They target specific cellular components or processes within the microbes, disrupting their vital functions and preventing their proliferation. These agents can be further classified based on their mechanism of action, such as bactericidal (kills bacteria) or bacteriostatic (inhibits bacterial growth).
The development of new antimicrobial agents is a continuous process due to the increasing threat of drug resistance. Pharmaceutical companies invest significant resources in research and development to discover and design novel compounds with improved efficacy and reduced side effects.
Several types of antimicrobial agents are available, including beta-lactams, macrolides, fluoroquinolones, aminoglycosides, and tetracyclines. Each class exhibits a distinct mode of action, making them suitable for treating specific types of infections. Additionally, combination therapies involving multiple antimicrobial agents are often employed to enhance effectiveness and combat resistance.
Antimicrobial agents are utilized not only in human medicine but also in veterinary and agricultural sectors to maintain the health and well-being of animals and plants. Strict regulations and quality control measures are in place to ensure the safety and efficacy of these pharmaceutical APIs.
In conclusion, antimicrobial agents are a crucial subcategory of pharmaceutical APIs that play a pivotal role in fighting microbial infections. Continuous research and development efforts are necessary to combat emerging drug resistance and ensure the availability of effective treatments for various infections.
Vindesine (Antimicrobial agents), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Vindesine API manufacturers & distributors
Compare qualified Vindesine API suppliers worldwide. We currently have 1 companies offering Vindesine API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Minakem | Producer | France | Belgium | CoA, EDMF/ASMF, GMP, JDMF | 31 products |
When sending a request, specify which Vindesine API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Vindesine API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
